ARCHIMED Acquires Esperion Therapeutics in Strategic Cardiometabolic Deal
Healthcare investment firm ARCHIMED announces definitive agreement to acquire Esperion Therapeutics, maker of cholesterol drugs NEXLETOL and NEXLIZET.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
